Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention
Davide Capodanno,Usman Baber,Deepak L. Bhatt,Jean-Philippe Collet,George Dangas,Francesco Franchi,C. Michael Gibson,Hyeon Cheol Gwon,Adnan Kastrati,Tsuyoshi Kimura,Pedro A. Lemos,Renato D. Lopes,Roxana Mehran,Michelle L. O'Donoghue,Sunil V. Rao,Fabiana Rollini,Patrick W. Serruys,Philippe Gabriel Steg,Robert F. Storey,Marco Valgimigli,Pascal Vranckx,Hirotoshi Watanabe,Stephan Windecker,Dominick J. Angiolillo +23 more
TL;DR: The authors describe the current evidence base and ongoing clinical trials into the use of P2Y12 inhibitor monotherapy after PCI, including supporting pharmacodynamic and clinical evidence, practical recommendations and future directions.
Journal ArticleDOI
Rationale, Design, and Baseline Data of the Japanese Primary Prevention Project (JPPP)-a Randomized, Open-Label, Controlled Trial of Aspirin Versus No Aspirin in Patients With Multiple Risk Factors for Vascular Events
Tamio Teramoto,Kazuyuki Shimada,Shinichiro Uchiyama,Masahiro Sugawara,Yoshio Goto,Nobuhiro Yamada,Shinichi Oikawa,Katsuyuki Ando,Naoki Ishizuka,Tsutomu Yamazaki,Kenji Yokoyama,Mitsuru Murata,Yasuo Ikeda +12 more
TL;DR: The JPPP is the largest primary prevention trial in a Japanese population that is investigating whether the benefit of aspirin in reducing risk of vascular events outweighs any bleeding risk in elderly patients with multiple risk factors.
Journal ArticleDOI
Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Melvin Lafeber,Wilko Spiering,Frank L.J. Visseren,Diederick E. Grobbee,Michiel L. Bots,Alice Stanton,Anushka Patel,Dorairaj Prabhakaran,Ruth Webster,Simon Thom,Anthony Rodgers +10 more
TL;DR: Switching to a polypill-based strategy resulted in estimated cardiovascular relative risk reductions across a wide range of usual care patterns of antiplatelet, statin and BP-lowering therapy prescribing, including equally potent or more potent regimens.
Journal ArticleDOI
Trends in peripheral arterial disease incidence and mortality in EU15+ countries 1990–2017:
Richard Goodall,Justin D. Salciccioli,Alun H. Davies,Alun H. Davies,Dominic C Marshall,Joseph Shalhoub,Joseph Shalhoub +6 more
TL;DR: Strong evidence supports goal- directed medical therapy in reducing PAD mortality - population-wide strategies to improve compliance to optimal goal-directed medical therapy are warranted.
Journal ArticleDOI
Impact of aspirin on the prognosis in patients with coronary spasm without significant atherosclerotic stenosis
Masanobu Ishii,Koichi Kaikita,Koji Sato,Kenshi Yamanaga,Takashi Miyazaki,Tomonori Akasaka,Noriaki Tabata,Yuichiro Arima,Daisuke Sueta,Kenji Sakamoto,Eiichiro Yamamoto,Kenichi Tsujita,Megumi Yamamuro,Sunao Kojima,Hirofumi Soejima,Seiji Hokimoto,Kunihiko Matsui,Hisao Ogawa +17 more
TL;DR: Low-dose aspirin might not reduce future cardiovascular events in VSA patients with non-significant stenosis, and major adverse cardiac events (MACE), defined as cardiac death, nonfatal myocardial infarction, and unstable angina are evaluated.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.